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Abstract 
Background: Hormone receptor-positive, human epidermal growth factor receptor-2-negative (HR+/HER2−) is the 
most common type of metastatic breast cancer (mBC). While mBC patients generally have poor prognosis with lim-
ited progression-free survival (PFS) and overall survival (OS), those with multiple metastatic sites may have even worse 
clinical outcomes due to multiple organ involvement. This study aimed to compare clinical outcomes including PFS, 
time on treatment (TOT), and OS between HR+/HER2− mBC patients with multiple metastases versus those with a 
single metastasis in a real-world clinical setting.
Methods: This was a retrospective chart review study of postmenopausal HR+/HER2− mBC women who had failed 
a non-steroidal aromatase inhibitor in the adjuvant or metastatic setting and initiated a new treatment for mBC 
between 07/01/2012 and 04/15/2013. Patients were classified to one of two study groups (multiple metastases or sin-
gle metastasis) based on the number of non-lymph-node metastases at the initiation of the new treatment. PFS, TOT 
and OS were compared between the two groups using Kaplan–Meier analyses and multivariable Cox proportional 
hazard models adjusting for patient disease and treatment characteristics. Separate Cox models were conducted 
including models with an interaction term between line of therapy and study group to assess the impact of multiple 
metastases on clinical outcomes across different lines of therapy.
Results: A total of 699 patient charts were collected, including 291 patients with multiple metastases and 408 
single metastasis patients. Worse performance status and a higher proportion of prior chemotherapy for mBC were 
observed among patients with multiple metastases. Overall, patients with multiple metastases had significantly 
shorter PFS [adjusted hazard ratio (HR) = 1.55, 95 % confidence interval (CI) 1.21–1.98], TOT (adjusted HR = 1.33, 95 % 
CI 1.05–1.67), and OS (adjusted HR = 1.77, 95 % CI 1.15–2.74) than single metastasis patients. Similar outcomes were 
observed in each line of therapy.
Conclusions: Among HR+/HER2− mBC patients, patients with multiple metastases had significantly shorter PFS, 
TOT, and OS than single metastasis patients, highlighting the substantial clinical burden and unmet need for more 
efficacious treatments for the former group of patients.
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Background
Breast cancer (BC) is the leading cancer among women 
[1]. In the US, approximately 230,000 new BC cases were 
diagnosed in 2014 and 40,000 people died of BC in the 
same year [2]. The majority of patients are diagnosed at 
the early stage, for which treatment is generally effective, 
with a 5-year survival rate nearing 90  % [2]. However, 
BC also has a high recurrence rate, with up to 40  % of 
patients eventually progressing to metastatic BC (mBC) 
[3, 4]. In addition, around 5 % of BC cases are diagnosed 
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at the metastatic stage [2]. Compared to early stage BC, 
mBC is associated with a much worse prognosis, with a 
5-year survival rate of only 25 % [2].
MBC is categorized in several histological subtypes, 
based on the presence, absence, or overexpression of 
certain cell receptors [4, 5]. Hormone receptor-positive 
(HR+)/human epidermal growth factor receptor-2-neg-
ative (HER2−) mBC accounts for the majority of mBC 
cases [5]. Treatment guidelines for HR+/HER2− mBC 
recommend the use of three consecutive lines of endo-
crine therapy before the initiation of chemotherapy, or an 
earlier switch to chemotherapy in patients with visceral 
symptoms or rapidly progressing/life-threatening dis-
ease [6]. Recently, new targeted therapies are emerging 
and may revolutionize the treatment of mBC [7, 8]. For 
HR+/HER2− mBC in particular, everolimus in combina-
tion with exemestane had superior efficacy in extending 
progression-free survival (PFS) compared to exemestane 
alone in the BOLERO-2 trial [9]. Studies also suggest that 
everolimus is associated with longer PFS and time on 
treatment (TOT) in postmenopausal women with HR+/
HER2− mBC [10, 11]. Palbociclib is another recently 
approved targeted therapy with demonstrated superior 
efficacy compared to endocrine therapy alone [12]. In 
addition, other targeted therapies with various mecha-
nisms of action are under development, and some may 
become available in the near future.
With the rapid changes in the treatment landscape, the 
main question faced by physicians and payers is identi-
fying the right patient population for these novel treat-
ments with superior efficacies. Patients who have poor 
prognosis have a greater unmet need and may benefit 
more from these treatments. Several real-world studies 
have examined prognostic factors in mBC; among these, 
the number of metastases has been shown to be a signifi-
cant predictor of overall survival (OS) [13–18]. However, 
these previous studies were all based on a single-center 
location and have generally focused only on OS [13–18]. 
While OS is an important outcome in mBC, other out-
comes would also be of interest from a clinical perspec-
tive, such as PFS and TOT. In addition, a study covering 
different geographic regions in the US would be more 
informative and less subject to practices specific to indi-
vidual centers.
To better understand clinical outcomes associated with 
multiple metastases, the current study was undertaken 
to compare PFS, TOT, and OS between HR+/HER2− 
mBC patients with multiple versus single metastases who 
were treated in community-based oncology practices 
in the US. The findings of this study could help us bet-
ter assess the unmet need in HR+/HER2− mBC among 
patients with multiple metastases in the US. The study 
provided updated evidence on mBC populations with 
greater unmet needs that can inform decision-makers on 
potential targets for novel treatments in lieu of the rap-
idly changing landscape of mBC treatment.
Results
Baseline characteristics
A total of 188 physicians contributed 699 patient charts, 
including 408 patients with a single site and 291 patients 
with multiple sites of metastasis (Table  1). Physicians 
were mostly male (>70  %), practicing in a small/inter-
mediate practice setting of 2–9 physicians (>70 %), and 
had more than 5  years of experience (>90  %). At index 
treatment initiation, the median patient age was 65 years 
for the multiple metastases group versus 64 years for the 
single metastasis group (Table  1). Both patient groups 
had similar median duration from initiation of the last 
adjuvant endocrine therapy to mBC diagnosis (19.2 vs. 
18.9 months, respectively) (Table 1). The median follow-
up duration from index treatment initiation was also 
similar between the two groups: 16.3  months among 
patients with multiple metastases and 16.7  months 
among patients with a single metastasis (p  =  0.239) 
(Table 1).
However, patients with multiple metastases had more 
aggressive mBC than patients with single metastasis. Spe-
cifically, at index treatment initiation, 77.0  % patients of 
the multiple metastases group had bone metastasis versus 
56.6 % of the single metastasis group, liver metastasis was 
present in 60.8 versus 11.5 % of cases, lung metastasis was 
present in 73.9 versus 21.3 % of cases, and brain metasta-
sis was present in 3.4 versus 0.5  % of cases, respectively 
(all p < 0.05) (Table 1). Multiple metastases patients also 
had a worse ECOG performance status than patients with 
single metastasis (ECOG ≥ 2 was recorded for 18.2 versus 
6.4 % of patients, respectively, p < 0.001) (Table 1). Twice 
as many patients with multiple metastases had used prior 
chemotherapy for mBC than patients with a single metas-
tasis (22.7 versus 10.3 %, p < 0.001) (Table 1).
Progression‑free survival (PFS)
In the overall sample, patients with multiple metasta-
ses had significantly shorter PFS than single metasta-
sis patients in both unadjusted (log-rank test p  <  0.001, 
hazard ratio (HR) =  1.98, 95 % confidence interval (CI) 
1.59–2.46, Fig.  1 and Table  2) and adjusted analyses 
(HR  =  1.55, 95  % CI 1.21–1.98, Table  2). Results were 
consistent across different lines of therapy, though any 
differences between the two groups were not significant 
in the first-line setting (Table 3). In addition, second-line 
treatment (versus first-line), bone metastasis (versus no 
bone metastasis), and worse ECOG performance sta-
tus were also associated with significantly shorter PFS 
(Table 2).
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Table 1 Patient baseline characteristics
Baseline characteristicsa Patients with multiple metastases Patients with a single metastasis P‑value†
N = 291 N = 408
Age at BC diagnosis, median years (range) 61.0 (35.0, 83.0) 61.0 (33.0, 90.0) 0.785
Age at index treatment initiation, median years (range) 65.0 (38.0, 86.0) 64.0 (33.0, 91.0) 0.878
Menopausal status at the first BC diagnosisb, n (%)
 Postmenopausal 169 (58.1) 238 (58.3) 0.946
Race, n (%)
 White 155 (53.3) 254 (62.3) 0.017*
 Non-white 136 (46.7) 154 (37.7)
Insurance plan type at mBC diagnosis, n (%)
 Commercial/private insurance 151 (51.9) 217 (53.2) 0.460
 Medicare only 115 (39.5) 166 (40.7)
 Others 25 (8.6) 25 (6.1)
Type of index treatment, n (%)
 Endocrine therapyc 196 (67.4) 356 (87.3) <0.001*
 Chemotherapyd 95 (32.6) 52 (12.7)
Line of index treatment, n (%)
 First line 81 (27.8) 206 (50.5) <0.001*
 Second line 97 (33.3) 97 (23.8)
 Third line and above 113 (38.8) 105 (25.7)
mBC type, n (%)
 Recurrent patients with adjuvant endocrine therapy 184 (63.2) 290 (71.1) 0.033*
 Recurrent patients without adjuvant endocrine therapy 39 (13.4) 54 (13.2)
 De novo 68 (23.4) 64 (15.7)
Number of non-lymph-node metastatic sites at mBC diagnosis, n (%)
 1 58 (19.9) 228 (55.9) <0.001*
 2 75 (25.8) 132 (32.4)
 3 132 (45.4) 8 (2.0)
 4 20 (6.9) 2 (0.5)
Sites of metastatic disease at mBC diagnosis, n (%)
 Bone 188 (64.6) 231 (56.6) 0.034*
 Liver 110 (37.8) 53 (13.0) <0.001*
 Lung 151 (51.9) 90 (22.1) <0.001*
 Any visceral metastasese 228 (78.4) 143 (35.0) <0.001*
 Brain 3 (1.0) 2 (0.5) 0.654
 Other 4 (1.4) 5 (1.2) 1.000
Number of non-lymph-node metastatic sites at index treatment initiation, n (%)
 1 0 (0.0) 374 (91.7) <0.001*
 2 208 (71.5) 0 (0.0)
 3 79 (27.1) 0 (0.0)
 4 4 (1.4) 0 (0.0)
Sites of metastatic disease at index treatment initiation, n (%)
 Bone 224 (77.0) 231 (56.6) <0.001*
 Liver 177 (60.8) 47 (11.5) <0.001*
 Lung 215 (73.9) 87 (21.3) <0.001*
 Any visceral metastasese 288 (99.0) 139 (34.1) <0.001*
 Brain 10 (3.4) 2 (0.5) 0.005*
 Other 6 (2.1) 2 (0.5) 0.073
Adjusted Charlson Comorbidity Index (CCI)f at index treatment 
initiation, median (range)
0.0 (0.0, 8.0) 0.0 (0.0, 6.0) 0.002*
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Time on treatment (TOT)
Overall, patients with multiple metastases had signifi-
cantly shorter TOT than single metastasis patients in 
both unadjusted (log-rank test p < 0.001, HR = 1.78, 95 % 
CI 1.46–2.18, Fig.  2 and Table  2) and adjusted analyses 
(HR = 1.33, 95 % CI 1.05–1.67, Table 2). Results across 
different lines resembled those in the overall sample, but 
were not significant (Table  3). Use of chemotherapy as 
index therapy, second-line treatment (versus first-line) 
and worse ECOG performance status were associated 
with significantly shorter TOT (Table 2).
Overall survival (OS)
Overall, patients with multiple metastases had signifi-
cantly shorter OS than single metastasis patients in both 
unadjusted (log-rank test p  <  0.001, HR  =  2.61, 95  % 
CI 1.78–3.83, Fig.  3 and Table  2) and adjusted analyses 
(HR = 1.77, 95 % CI 1.15–2.74, Table 2). Results across 
different lines also resembled those in the overall sam-
ple and were significant in the first- and second-line set-
tings  (Table  3). Use of chemotherapy as index therapy, 
higher adjusted Charlson comorbidity index (CCI), worse 
ECOG performance score, and prior chemotherapy 
for mBC were associated with significantly shorter OS 
(Table 2).
BC breast cancer, ECOG Eastern Cooperative Oncology Group, mBC metastatic breast cancer
* p < 0.05
†  Statistical comparisons were conducted using Wilcoxon rank-sum tests for continuous variables and Chi square tests for categorical variables
a Disease characteristics described at new treatment initiation include age, treatment type, line of index treatment, number and sites of metastases, adjusted CCI, 
ECOG performance status, and prior chemotherapy for mBC. Menopausal status, race, insurance plan type, mBC type, number and sites of metastases, and time 
elapsed (months) from initiation of last adjuvant endocrine therapy to stage IV mBC diagnosis were assessed at mBC diagnosis. Duration from initiation of index 
treatment to available follow-up was assessed at the end of follow-up
b The exact variable for menopausal status was not collected in the study but instead imputed based on age (postmenopausal: age ≥60)
c Endocrine therapy includes endocrine monotherapy (anastrozole, exemestane, fluoxymesterone, fulvestrant, letrozole, megestrol acetate, tamoxifen), combination 
therapy with two endocrine agents (fulvestrant + anastrozole, fulvestrant + exemestane, fulvestrant + exemestane, fulvestrant + tamoxifen), and everolimus-based 
therapies (everolimus, everolimus + anastrozole, everolimus + exemestane, everolimus + fulvestrant, everolimus + letrozole)
d Chemotherapy includes chemotherapy monotherapy (capecitabine, docetaxel, gemcitabine, ixabepilone, paclitaxel, protein-bound paclitaxel, vinorelbine), 
combinational therapy of two chemotherapy agents (cyclophosphamide + docetaxel, cyclophosphamide + doxorubicin, doxorubicin + docetaxel, 
paclitaxel + gemcitabine), and combinational therapy of chemotherapy and endocrine therapy (anastrozole + paclitaxel, fulvestrant + capecitabine, 
fulvestrant + paclitaxel, letrozole + paclitaxel)
e Any visceral metastases refer to liver, lung, and other visceral metastases, including peritoneum, adrenal gland, and kidney
f The adjusted CCI calculates the comorbidity index excluding metastatic breast cancer (score of 6)
Table 1 continued
Baseline characteristicsa Patients with multiple metastases Patients with a single metastasis P‑value†
N = 291 N = 408
ECOG performance status at index treatment initiation, n (%)
 0 49 (16.8) 134 (32.8) <0.001*
 1 151 (51.9) 164 (40.2)
 2 45 (15.5) 24 (5.9)
 3 8 (2.7) 2 (0.5)
 Not recorded in medical record 38 (13.1) 84 (20.6)
Use of chemotherapy for mBC before index treatment initiation,  
n (%)
66 (22.7) 42 (10.3) <0.001*
Duration from initiation of last adjuvant endocrine therapy to mBC 
diagnosis, median months (range)
19.2 (0.0, 216.6) 18.9 (0.0, 130.8) 0.879
Duration from initiation of index treatment to available follow-up, 
median months (range)
16.3 (1.0, 25.2) 16.7 (1.0, 24.6) 0.239
Fig. 1 Comparison of progression-free survival between HR+/
HER2− mBC patients with multiple metastases versus single metas-
tasis
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Discussion
With advancements in the treatment of HR+/HER2- 
mBC, it is important to identify the patients who are in 
greater need of innovative therapies. Previous studies have 
identified multiple metastases as a risk factor for shorter 
OS. The current study added to the literature by using a 
national sample of mBC patients and comparing multiple 
clinical outcomes (PFS, TOT and OS) between patients 
with multiple metastases versus those with a single metas-
tasis. The results demonstrate that patients with multiple 
metastases had significantly worse outcomes, as measured 
by PFS, TOT and OS, even after controlling for other fac-
tors, including bone metastasis. The findings are consist-
ent across different lines of therapy. The current study 
confirms that the presence of multiple metastases is an 
independent prognostic factor of worse clinical outcomes 
among postmenopausal HR+/HER2- mBC patients. Fur-
thermore, consistent with previous literature [14, 19–25], 
ECOG performance status was independently and sig-
nificantly associated with all clinical outcomes examined 
in this study. Bone metastasis was significantly associated 
with PFS but not with other outcomes.
Table 2 Comparisons of progression-free survival, time on treatment, and overall survival, between patients with multi-
ple metastases versus single metastasis
BC breast cancer, CCI Charlson Comorbidity Index, CI confidence interval, ECOG Eastern Cooperative Oncology Group, HR hazard ratio, mBC metastatic breast cancer, 
Ref reference
* P < 0.05; Ref reference group
a The model adjusted for age, race, insurance type at mBC diagnosis, treatment type, line of the index treatment, mBC type, adjusted CCI, bone metastasis at index 
therapy initiation, ECOG performance status, prior chemotherapy for mBC, and months from the initiation of the last adjuvant endocrine therapy to mBC diagnosis
b Endocrine therapy includes endocrine monotherapy, combination therapy with another endocrine agent, and everolimus-based therapies
c Chemotherapy includes chemotherapy monotherapy, combinational therapy of chemotherapy agents, and combinational therapy of chemotherapy and endocrine 
therapy
Parameters Progression‑free survival Time on treatment Overall survival
HR (95 % CI) P‑value  HR (95 % CI) P‑value HR (95 % CI) P‑value
Univariate analysis
 Multiple metastases (Ref: single metastasis) 1.98 (1.59,2.46) <0.001* 1.78 (1.46, 2.18) <0.001* 2.61 (1.78, 3.83) <0.001*
Multivariable-adjusted analysisa
 Multiple metastases (Ref: single metastasis) 1.55 (1.21,1.98) <0.001 1.33 (1.05, 1.67) 0.018* 1.77 (1.15, 2.74) 0.010*
 Age at index therapy initiation 0.98 (0.97,1.00) 0.043* 0.97 (0.95, 0.99) <0.001* 1.01 (0.98, 1.04) 0.646
 Race (Ref: non-white)
  White 0.89 (0.71,1.12) 0.331 0.83 (0.67, 1.02) 0.074 0.88 (0.61, 1.29) 0.527
Insurance at mBC diagnosis (Ref: other or no insurance)
 Private 1.35 (0.85,2.14) 0.203 1.23 (0.81, 1.87) 0.326 1.12 (0.50, 2.50) 0.787
 Medicare only 1.47 (0.89,2.42) 0.128 1.46 (0.93, 2.31) 0.103 1.27 (0.53, 3.04) 0.584
Type of index treatment (Ref: endocrine therapyb)
 Chemotherapyc 1.18 (0.91,1.55) 0.216 2.29 (1.80, 2.90) <0.001* 1.84 (1.20, 2.81) 0.005*
Line of index treatment (Ref: first-line)
 Second-line 1.49 (1.06,2.09) 0.023* 1.75 (1.27, 2.41) 0.001* 1.26 (0.69, 2.29) 0.448
 Third-line and above 1.34 (0.93,1.93) 0.114 1.18 (0.84, 1.65) 0.337 0.85 (0.44, 1.63) 0.618
mBC type (Ref: de novo)
 Recurrent with adjuvant endocrine therapy 1.27 (0.90,1.78) 0.175 1.53 (1.11, 2.12) 0.010* 1.40 (0.73, 2.64) 0.316
 Recurrent without adjuvant endocrine therapy 0.40 (0.25,0.66) <0.001* 0.45 (0.29, 0.71) 0.001* 1.06 (0.49, 2.31) 0.882
 Adjusted CCI at index treatment initiation 1.08 (0.97,1.20) 0.155 1.09 (0.99, 1.21) 0.084 1.20 (1.02, 1.40) 0.024*
Bone metastasis at index therapy initiation
 (Ref: no bone metastasis) 1.56 (1.20,2.02) 0.001* 1.15 (0.91, 1.45) 0.233 0.85 (0.57, 1.27) 0.418
Performance status at index treatment initiation (Ref: ECOG 0)
 ECOG 1 1.44 (1.06,1.97) 0.021* 1.04 (0.79, 1.37) 0.785 1.76 (0.93, 3.32) 0.080
 ECOG 2 and 3 2.60 (1.70,3.98) <0.001* 1.87 (1.26, 2.78) 0.002* 5.04 (2.45, 10.40) <0.001*
 Unknown 1.77 (1.20,2.62) 0.004* 1.29 (0.90, 1.83) 0.166 3.15 (1.47, 6.72) 0.003*
Use of chemotherapy for mBC before index treatment initiation 0.82 (0.58,1.17) 0.283 0.89 (0.65, 1.23) 0.484 2.02 (1.15, 3.55) 0.014*
Duration from initiation of last adjuvant endocrine therapy to mBC 
diagnosis
1.00 (0.99,1.00) 0.374 1.00 (0.99, 1.00) 0.016* 1.00 (0.99, 1.01) 0.671
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Due to multiple organ involvement, patients with mul-
tiple metastases are likely to be sicker and have more 
severe mBC than single metastasis patients [23, 26–28]. 
In the current study, patients with multiple metastases 
had a higher adjusted CCI score, worse ECOG perfor-
mance status, and higher use of prior chemotherapy for 
mBC than single metastasis patients. The differences in 
clinical outcomes are quite striking between patients 
with multiple metastases and those with a single metas-
tasis. The former group had a 55 % higher hazard of expe-
riencing progression or death and a 77 % higher hazard 
of death, even after controlling for other potential prog-
nostic factors of mBC (e.g., ECOG performance status). 
This impact was evident across different lines of ther-
apy. These findings highlight the substantial burden and 
unmet need for more efficacious treatments in patients 
with multiple metastases.
In real-world practice, patients with multiple metas-
tases are more likely to receive chemotherapy, often 
because their vital organs are affected and the patients 
are thus perceived to be in “visceral crisis” [29, 30]. 
However, chemotherapy is associated with serious side 
effects and can substantially impair patients’ quality 
of life [31, 32]. More importantly, chemotherapy has 
limited efficacy and effectiveness [11, 33]. These limi-
tations call for more effective treatments to address 
the substantial unmet need of patients with multiple 
metastases.
Recently, a number of novel targeted therapies for the 
treatment of HR+/HER2− mBC have been approved or 
Table 3 Comparisons of progression-free survival, time on treatment, and overall survival between patients with multi-
ple metastases versus single metastasis by line of therapy
CCI Charlson Comorbidity Index, CI confidence interval, ECOG Eastern Cooperative Oncology Group; HR hazard ratio, mBC metastatic breast cancer, Ref reference
* P < 0.05
a The model adjusted for the following variables: age, race, insurance type at mBC diagnosis, treatment type, mBC type, adjusted CCI, bone metastasis at index 
therapy initiation, ECOG performance status, prior chemotherapy for mBC, and months from the initiation of the last adjuvant endocrine therapy to mBC diagnosis
Multiple metastases (Ref: single metastasis) Progression‑Free Survival Time on Treatment Overall Survival
HR (95 % CI) P‑value  HR (95 % CI) P‑value HR (95 % CI) P‑value
Univariate analysis
 First-line 1.87 (1.32, 2.65) <0.001* 1.79 (1.30, 2.47) <0.001* 3.32 (1.88, 5.85) <0.001*
 Second-line 2.01 (1.33, 3.03) 0.001* 1.83 (1.26, 2.65) 0.001* 3.29 (1.48, 7.33) 0.004*
 Third-line and above 2.33 (1.54, 3.53) <0.001* 2.04 (1.37, 3.02) <0.001* 1.93 (0.94, 3.95) 0.074
Multivariate-adjusted analysisa
 First-line 1.43 (0.99, 2.08) 0.059 1.20 (0.85, 1.69) 0.313 1.98 (1.08, 3.64) 0.028*
 Second-line 1.69 (1.10, 2.59) 0.017* 1.47 (0.99, 2.17) 0.055 2.41 (1.05, 5.52) 0.038*
 Third-line and above 1.57 (1.00, 2.46) 0.049* 1.38 (0.90, 2.11) 0.143 1.09 (0.50, 2.36) 0.832
Fig. 2 Comparison of time on treatment between HR+/HER2− mBC 
patients with multiple metastases versus single metastasis
Fig. 3 Comparison of overall survival between HR+/HER2− mBC 
patients with multiple metastases versus single metastasis
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are in late-stage clinical development, including mam-
malian target of rapamycin (mTOR) inhibitors (e.g., 
everolimus), cyclin dependent kinase (CDK)-4/6 inhibi-
tors (e.g., palbociclib), and phosphoinositide 3-kinase 
(PI3k) inhibitors (e.g., buparlisib). Large phase III ran-
domized controlled trials (RCTs) have demonstrated 
the superior efficacy of these treatments compared to 
conventional endocrine monotherapies. For example, 
the median PFS associated with everolimus/exemestane 
combinational therapy was nearly three times longer 
than the PFS observed with exemestane monotherapy 
in the BOLERO-2 trial [9], and first-line palbociclib/
letrozole combinational therapy doubled the PFS of 
patients receiving this treatment compared to patients 
treated with letrozole monotherapy in the PALOMA-1 
trial [12]. In addition, everolimus-based therapy was also 
shown to be associated with significantly longer OS and 
PFS relative to endocrine therapy and chemotherapy 
[10, 11]. These innovative treatments may substantially 
improve outcomes among patients with multiple metas-
tases. However, current literature suggests that individual 
treatment regimens are similar between first-line and 
subsequent lines of treatment [30, 33–36], and clinical 
guidelines have not recommended an optimal treatment 
sequence for the treatment of HR+/HER2− mBC [6, 
37]. With a rapidly evolving treatment landscape, more 
studies are needed to assess the effects of newer treat-
ments in this population and to shed light on the optimal 
sequencing of endocrine therapy, targeted therapy, and 
chemotherapy.
Adding to the previous literature, the current study 
could provide important evidence for decision-makers. 
From the physician perspective, identifying the patients 
who need more advanced treatment could facilitate a 
targeted approach to mBC management. For payers and 
health policy makers, understanding the burden of differ-
ent subgroups of mBC could help in optimizing resource 
allocation for those in greater need of advanced treat-
ment and could result in the improvement of the overall 
outcomes of mBC patients through a more cost-effec-
tive approach. Finally, the implications of more effective 
treatment go beyond extending PFS and OS. Such thera-
pies may also improve the quality of life and productivity 
of patients. Therefore, the benefits of applying advanced 
treatments in this group with high unmet needs could 
be more substantial when viewed from the societal 
perspective.
This study has several limitations inherent to retro-
spective chart review studies. First, the results might be 
subject to selection bias if confounding factors were not 
identified or adjusted for in the analyses [38, 39]. In the 
current study, we adjusted for important baseline char-
acteristics that were available in patient charts and which 
were thought to have the potential to affect clinical out-
comes. Second, the frequency of follow-up could have 
differed between the two patient groups. Patients with 
multiple metastases had more severe mBC and may have 
been followed up more frequently than single metastasis 
patients. Thus, they may have been more likely to be iden-
tified as experiencing an event (e.g., progression) and this 
cohort may be biased against in the time-to-event analy-
ses. Third, the current study did not collect any biopsy or 
histology data, which are important indicators to confirm 
mBC and inform treatment choice. Fourth, all patients 
were required to be postmenopausal at index treatment 
initiation based on eligibility criteria, but this study did 
not collect detailed menopausal status at BC diagnosis 
or mBC diagnosis. Despite these limitations, the current 
study provides important insights about real-world clini-
cal outcomes for HR+/HER2− mBC patients with multi-
ple metastases from a large nationwide sample, and could 
further help clinical and policy decision-making.
Conclusion
Among HR+/HER2− mBC patients treated in commu-
nity-based oncology practices in the US, those with mul-
tiple metastases had significantly shorter PFS, TOT, and 
OS than single metastasis patients, highlighting a sub-
stantial clinical burden and unmet need for more effec-
tive treatments for these high-risk patients.
Methods
Data source and patient selection
Community-based oncologists and hematologists who 
treated post-menopausal women with HR+/HER2− 
stage IV mBC (excluding patients with locoregional 
recurrences) were invited to participate in this chart 
review study from a nationwide online panel of over 9500 
physicians practicing in the US. Participants were asked 
to randomly select up to ten eligible patients and enter 
relevant patient chart information into a secure elec-
tronic case report form (CRF). The CRF was developed 
by the study investigators and pilot tested with three phy-
sicians. No patient identification information was col-
lected, and the study was approved by the New England 
Institutional Review Board.
Patients were eligible for this study if they had BC 
recurrence or progression on or after a non-steroidal 
aromatase inhibitor in the adjuvant or metastatic set-
ting, and had initiated a new treatment for mBC, 
defined as the index treatment, between 07/01/2012 
and 04/15/2013. Patients enrolled in any clinical trial or 
with a history of primary non-BC malignancy (with the 
exception of non-melanoma skin cancer and carcinoma 
in situ of the cervix uteri) during the 3 years prior to the 
first mBC diagnosis date were excluded. Patients were 
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classified into two study groups based on the number of 
non-lymph-node metastatic sites at index treatment ini-
tiation: multiple metastases versus single metastases.
Study outcome measures
PFS, TOT, and OS were assessed. PFS was defined as the 
time from index treatment initiation to disease progres-
sion or death, whichever occurred first. Progression was 
determined by the physician, based on radiographic evi-
dence or tests, physical exams, symptoms, or other meth-
ods. TOT was defined as the time from index treatment 
initiation to discontinuation of the index treatment or 
death, whichever occurred first. OS was defined as the 
time from index treatment initiation to death from any 
cause. For all outcomes, patients who did not have an 
event at the end of the study were censored at the date of 
last follow-up.
Statistical analysis
Patient baseline characteristics (i.e., before index treat-
ment initiation) were compared between the two study 
groups using Wilcoxon rank-sum tests for continuous 
variables and Chi square tests for categorical variables. 
Patient characteristics included age, menopausal sta-
tus (imputed based on age, postmenopausal: age ≥60), 
race, insurance type, type of index treatment (endocrine 
or chemotherapy), line of index treatment, mBC type, 
number of non-lymph-node metastases, sites of meta-
static disease, adjusted CCI (excluding a score of six for 
metastatic cancer), ECOG performance status, prior 
chemotherapy for mBC, the time elapsed from the ini-
tiation of the last adjuvant endocrine therapy to mBC 
diagnosis, and duration from the initiation of the index 
treatment to end of follow-up.
PFS, TOT and OS were compared between patients 
with multiple and single metastases using Kaplan–Meier 
curves with log-rank tests and univariate Cox regression 
models. These outcomes were also compared between the 
two groups using multivariable Cox regression models 
adjusting for age at index treatment initiation, race, insur-
ance type at mBC diagnosis, treatment type, line of the 
index treatment, mBC type, adjusted CCI, bone metasta-
sis at index therapy initiation, ECOG performance status, 
prior chemotherapy for mBC, and time elapsed (months) 
from the initiation of the last adjuvant endocrine therapy 
to mBC diagnosis. In addition, separate Cox proportional 
hazard models were conducted, which included an inter-
action term between the line of therapy and study group 
in order to assess the impact of multiple metastases on 
clinical outcomes across different lines of therapy.
All analyses used a two-sided p value of 0.05 to deter-
mine statistical significance. Analyses were performed 
using SAS 9.3 (Cary, NC, USA).
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